Patient Square leads $145m round for Apollo Therapeutics

Also taking part in the funding round were Rock Springs Capital, Reimagined Ventures and UCL Technology Fund.

The Cambridge-based company will use the proceeds to advance its lead therapeutic programmes into clinical development. It also hopes to expand its UK operations in the Cambridge area, and in the US with a new facility in Boston. 

As part of the financing, Patient Square managing partner Jim Momtazee will join Apollo's board of directors. Richard Butt, who has been with Apollo since its inception, will serve as the company's chief scientific officer. Jamie Heath will join the company as chief financial officer and Arjun Krishnan as chief business officer. Ian Tomlinson, who previously chaired Apollo's investment committee, will join the board as a non-executive director.

Company
Apollo was established in 2015 as a joint venture between the University of Cambridge, Imperial College London (then subsequently IP Group), University College London, AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation.

The company is headquartered in Cambridge and currently has 15 therapeutic programmes in development across oncology, major inflammatory disorders and rare disease. It has fewer than 50 staff. 

People
Apollo – Richard Mason (CEO).
Patient Square – Jim Momtazee (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Venture
• United Kingdom